Lead Discovery Center GmbH - Product Pipeline Review

Global Markets Direct’s, ‘Lead Discovery Center GmbH - Product Pipeline Review, 2016’, provides an overview of the Lead Discovery Center GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lead Discovery Center GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Lead Discovery Center GmbH

The report provides overview of Lead Discovery Center GmbH including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Lead Discovery Center GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Lead Discovery Center GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Lead Discovery Center GmbH’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Lead Discovery Center GmbH

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lead Discovery Center GmbH’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Lead Discovery Center GmbH Snapshot 8

Lead Discovery Center GmbH ...

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Lead Discovery Center GmbH Snapshot 8

Lead Discovery Center GmbH Overview 8

Key Information 8

Key Facts 8

Lead Discovery Center GmbH - Research and Development Overview 9

Key Therapeutic Areas 9

Lead Discovery Center GmbH - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Partnered Products 15

Partnered Products/Combination Treatment Modalities 16

Pipeline Products - Out-Licensed Products 17

Out-Licensed Products/Combination Treatment Modalities 18

Lead Discovery Center GmbH - Pipeline Products Glance 19

Lead Discovery Center GmbH - Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Lead Discovery Center GmbH - Drug Profiles 22

Small Molecule for Target RhoGEF12 for Cardiovascular Disease 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecule to Activate Beclin1 for Neurodegenerative Diseases and Viral Infections 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecules to Antagonize RON Kinase for Oncology 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecules to Inhibit Cyclophilin for Immunology and Respiratory Disorders 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

englerin A 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule 1 for Oncology 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule 2 for Oncology 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecule 3 for Oncology 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Small Molecule 4 for Oncology 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecule for AMD, Inflammation and Oncology 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule for Amyotrophic Lateral Sclerosis 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecule for Chlamydia Infections 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small molecule for Multiple Sclerosis 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule for Oncology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecule to Activate TRIM32 for Neurodegenerative Diseases 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecule to Agonize P2Y6R for Type 2 Diabetes 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecule to Block TRPC4 and TRPC5 for Cardiovascular Disease and Epilepsy 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecule to Inhibit AML1/ETO for Acute Myeloid Leukemia 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecule to Inhibit CDK12 and CDK13 for Oncology 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecule to Inhibit Chemerin for Inflammation 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecule to Inhibit degS Serine Endoprotease for Bacterial Infections 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Small Molecule to Inhibit GLUT1 for Oncology 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Small Molecule to Inhibit GRK5 for Type 2 Diabetes 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecule to Inhibit MARK2 for Alzheimer's Disease 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecule to Inhibit Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecule to Inhibit RabGGTase for Solid Tumors 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Small Molecule to Inhibit SFRP1 for Oncology 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Small Molecule to Inhibit Steroid Sulfatase for Oncology 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Small Molecule to Target Draxin for Oncology 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Small Molecule to Target Hedgehog Pathway for Oncology 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Small Molecule to Target K-Ras/PDE Delta for Oncology 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Small Molecule to Target Nrg1-ErbB4 Pathway for Schizophrenia and Cardiovascular Diseases 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Small Molecule to Target SLC6A15 for Major Depressive Disorder 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecules 1 for Oncology 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecules for Charcot-Marie-Tooth Disease Type I A 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecules for Influenza 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules for Lung Cancer 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecules for Oncology 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecules to Activate GFAT for Alzheimer’s Disease 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Small Molecules to Inhibit LRRK2 for Parkinson's Disease 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Small Molecules to Inhibit NET Formation for Sepsis and SLE 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Small Molecules to Target Notch Signaling Pathway for Oncology 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Small Molecules to Target SIRT7 for Cardiovacular Diseases, Metabolic Syndrome and Oncology 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Lead Discovery Center GmbH - Pipeline Analysis 67

Lead Discovery Center GmbH - Pipeline Products by Target 67

Lead Discovery Center GmbH - Pipeline Products by Molecule Type 69

Lead Discovery Center GmbH - Pipeline Products by Mechanism of Action 70

Lead Discovery Center GmbH - Recent Pipeline Updates 72

Lead Discovery Center GmbH - Dormant Projects 73

Lead Discovery Center GmbH - Locations And Subsidiaries 74

Head Office 74

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

List of Tables

Lead Discovery Center GmbH, Key Information 8

Lead Discovery Center GmbH, Key Facts 8

Lead Discovery Center GmbH - Pipeline by Indication, ...

List of Tables

Lead Discovery Center GmbH, Key Information 8

Lead Discovery Center GmbH, Key Facts 8

Lead Discovery Center GmbH - Pipeline by Indication, 2016 10

Lead Discovery Center GmbH - Pipeline by Stage of Development, 2016 13

Lead Discovery Center GmbH - Monotherapy Products in Pipeline, 2016 14

Lead Discovery Center GmbH - Partnered Products in Pipeline, 2016 15

Lead Discovery Center GmbH - Partnered Products/ Combination Treatment Modalities, 2016 16

Lead Discovery Center GmbH - Out-Licensed Products in Pipeline, 2016 17

Lead Discovery Center GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016 18

Lead Discovery Center GmbH - Preclinical, 2016 19

Lead Discovery Center GmbH - Discovery, 2016 20

Lead Discovery Center GmbH - Pipeline by Target, 2016 67

Lead Discovery Center GmbH - Pipeline by Molecule Type, 2016 69

Lead Discovery Center GmbH - Pipeline Products by Mechanism of Action, 2016 70

Lead Discovery Center GmbH - Recent Pipeline Updates, 2016 72

Lead Discovery Center GmbH - Dormant Developmental Projects,2016 73

List of Figures

List of Figures

Lead Discovery Center GmbH - Pipeline by Top 10 Indication, 2016 10

Lead Discovery Center GmbH - Pipeline by Stage of Development, ...

List of Figures

Lead Discovery Center GmbH - Pipeline by Top 10 Indication, 2016 10

Lead Discovery Center GmbH - Pipeline by Stage of Development, 2016 13

Lead Discovery Center GmbH - Monotherapy Products in Pipeline, 2016 14

Lead Discovery Center GmbH - Partnered Products in Pipeline, 2016 15

Lead Discovery Center GmbH - Out-Licensed Products in Pipeline, 2016 17

Lead Discovery Center GmbH - Pipeline by Top 10 Target, 2016 67

Lead Discovery Center GmbH - Pipeline by Molecule Type, 2016 69

Lead Discovery Center GmbH - Pipeline Products by Top 10 Mechanism of Action, 2016 70

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports